Hercules Capital, Inc. (0J4M.L)
| Previous close | 19.17 |
| Open | 19.19 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 19.15 - 19.20 |
| 52-week range | 11.48 - 19.20 |
| Volume | |
| Avg. volume | 3,126 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | 0.21 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Hercules Capital Declares a Total Cash Distribution of $0.48 per Share for the First Quarter 2024
SAN MATEO, Calif., April 30, 2024--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), the largest and leading specialty finance provider to innovative, venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, is pleased to announce that its Board of Directors has declared a first quarter 2024 total cash distribution of $0.48 per share. The following shows the key dates of the first quarter 2024 dis
- PR Newswire
SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab
SynOx Therapeutics Limited ("SynOx" or the "Company"), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, today announces it has entered into a $35m loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules").
- Business Wire
Hercules Capital Celebrates 20th Anniversary with $20.0 Billion in Cumulative Originations
SAN MATEO, Calif., April 24, 2024--Hercules Capital, Inc. (NYSE: HTGC) ("Hercules" or the "Company"), is celebrating its 20th year of originations activity by reaching the $20.0 billion milestone in total debt commitments.
